Apriori Bio is learning about viruses present today to prepare for outbreaks in the future. The most threatening viruses can evolve faster than new medicines can be developed. To solve this, Apriori built their technology platform, Octavia, which gets ahead of viral evolution by identifying the variants that present the greatest threats. Octavia generates maps of existing and potential variants based on their ability to bind human cells and evade antibody recognition. With this information, Apriori can identify the combination of antibodies that can best protect against current and future viruses. The tools involved in the platform include protein display systems, deep mutational scanning, single-cell sorting and deep sequencing.

<p>Harmful viruses continue to evolve, and Apriori Bio’s goal is to provide humanity with variant-proof protection against these viruses. To achieve that goal, Apriori is building a platform, called Octavia, to design vaccines and antibody drugs that combat existing and potential viral variants. The Octavia platform applies protein display, mutational scanning, single-cell sorting, and deep sequencing to create maps of potential viral variants based on their ability to bind human cells and evade antibodies. Apriori analyzes these maps to identify protective antibody combinations and inform development of new vaccines and antibody drugs. Apriori envisions a future where our vaccines and antibody drugs protect us from not only an existing virus but its future variants that are likely to emerge.</p>


Apriori Bio

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori BioLearn More

Flagship Pioneering Launches Apriori Bio to Provide Variant-Proof Protection from the Greatest Viral ThreatsLearn More

We are thrilled to announce Craig Williams as Chief Executive Officer of Apriori. Since joining as President last year, Craig has been instrumental in driving Apriori’s operations, building out its early pipeline and increasing its global reach, securing key sources of funding and collaboration, and growing the team.

Read more about Craig and his vision for Apriori: https://lnkd.in/eTXwFJQz 

#FlagshipFounded

We recently caught up with Director of Data Science Max Winston, PhD, to hear how he is leading our team of data scientists as we advance our Octavia™ platform.

“The vision we are working towards—providing humanity with variant-resilient protection against rapidly evolving viruses—is ambitious and involves everyone at Apriori. I am inspired by our team, the collaborative environment we’re building, and the progress we’re making on a daily basis,” he said.

Read our full Q&A with Max below.

#AprioriLife #WeAreHiring #JoinUs

Apriori Bio Appoints Harry Kleanthous, Ph.D., as Chief Scientific OfficerLearn More

Apriori President Craig Williams recently joined other global healthcare leaders on a panel at the UNGA Science Summit 2024 to discuss pandemic preparedness and the importance of data to improve decision-making and global health outcomes. Craig spoke about our work to help provide humanity with variant-resilient protection against rapidly-evolving viruses, and the need to invest in infrastructure now to prevent future pandemics. 
 
Thank you to Airfinity Ltd for organizing this important conversation. #SSUNGA79 #FlagshipFounded

Apriori Bio Appoints Harry Kleanthous, Ph.D., as Chief Scientific Officer - PR Newswire

Apriori Bio Appoints World-Class Vaccine, Immunology and Public Health Leaders to Board of Directors - PR Newswire

 Apriori receives funding boost from CEPI to advance AI platform to protect against viral threats 

 Apriori Bio Appoints Harry Kleanthous, Ph.D., as Chief Scientific Officer 

Proactively protecting health through preemptive medicine is a key pillar of our work at Apriori. We are excited to work with Raj Panjabi as he steps in to lead the Preemptive Health and Medicine Initiative at Flagship Pioneering. He has deep experience, both as a physician and serving in the Biden administration, tackling some of the world’s biggest public health challenges. His insights will help us develop variant-resilient vaccines to protect humanity against viral threats.

Citeline’s Eliza Slawther wrote about how Apriori is leading the way in vaccine development by leveraging AI and machine learning to design variant-resilient vaccines. 
 
Our CEO Lovisa Afzelius commented on the importance of shifting away from the reactive way in which vaccines have previously been developed and distributed. 

Read more about how we are using our platform Octavia™ to get ahead of future viral outbreaks: https://lnkd.in/ekYzn7zd

Apriori Bio Named 2023 Technology Pioneer by World Economic ForumLearn More

 Apriori Bio Raises $1.1M in Funding 

Apriori receives funding boost from CEPI to advance AI platform to protect against viral threats - CEPI

Flagship launches Metaphore with $50M to mimic the molecular version of the owl butterfly - Fierce Biotech

AI-made drug starts human trials - Semafor

Flagship Pioneering Launches Apriori Bio to Provide Variant-Proof Protection from the Greatest Viral Threats - PR Newswire

Apriori Bio Appoints World-Class Vaccine, Immunology and Public Health Leaders to Board of DirectorsLearn More

This biotech incubator has built 100+ companies by asking, What if . . . ? - Fast Company

It’s been an exciting year for Apriori. We celebrated Craig Williams stepping into his new role as CEO, welcomed our Board of Directors and our Chief Scientific Officer Harry Kleanthous, secured new funding from CEPI (Coalition for Epidemic Preparedness Innovations), and helped advance the global conversation about the future of vaccines.
 
We are grateful for our team’s relentless dedication to our mission. Here’s to another fantastic year ahead. 

#AprioriLife #FlagshipFounded #JoinUs

Join us in welcoming Harry Kleanthous to the Apriori team as our Chief Scientific Officer. Harry's 30+ years of experience and leadership at biotech and large biopharma companies will be a tremendous asset as we work to better protect humanity against rapidly-evolving viruses.   
 
Learn more about what he brings to our team: https://lnkd.in/e8e-c6GV #FlagshipFounded

We sat down with principal scientist Kevin Olivieri to hear about his background in virology and why he believes the Apriori team’s work can make a positive impact on human health.   

“Apriori is a great company with enormous potential to change human health in a positive way. The team is exceptional in their creativity, thoughtfulness, and ability to recognize how our work plays into the bigger picture,” he shared.

Read our full Q&A with Kevin below.

#AprioriLife #WeAreHiring #JoinUs

It’s not every day you get to see your name (and larger than life face) in Times Square. 

What an incredible way to celebrate my new role as CEO of Apriori Bio with my family and friends. Thank you Nasdaq for the warm welcome. 

As I step into this new role, I am profoundly grateful for the journey that has brought me here- especially for the times that weren’t so easy. And I am eternally thankful for the family and friends who continue to support and embrace me in spite of and because of my differences. 

It may be a new role, but it’s the same mission- make the world a safer, healthier, better place. 

Now, let’s get to work!

We're pleased to welcome Seth Berkley, Arup Chakraborty, and Ashish Jha to our Board of Directors. These world-class vaccine, immunology, and public health leaders will join Board Chair Lovisa Afzelius and Travis Wilson, Growth Partner at Flagship Pioneering, in supporting our leadership team as they advance our mission to protect humanity against viral threats. 
 
Their expertise in vaccine development and public health will be instrumental as we expand our biology-informed AI platform, Octavia™, to develop variant-resilient protection against rapidly-evolving viruses. 
 
Read the full press release to learn more: https://lnkd.in/ePXt6s_r

#FlagshipFounded

Apriori Bio

Business:

About: